NCT07156773View on ClinicalTrials.gov

The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 3, 2025

Primary Completion Date

March 30, 2026

Study Completion Date

April 30, 2026

Conditions
Parkinson Disease
Interventions
DRUG

XJN010 Nasal Spray

"In the XJN010 Nasal Spray group, subjects will receive XJN010 Nasal Spray，Based on the frequency of the off periods experienced by Parkinson's patients."

DRUG

Placebo

"In the XJN010 Nasal Spray blank preparation group, subjects will receive XJN010 Nasal Spray blank preparation, Based on the frequency of the off periods experienced by Parkinson's patients ."

Trial Locations (1)

511434

RECRUITING

The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital), Guangzhou

All Listed Sponsors
lead

Guangzhou Novaken Pharm Co., Ltd.

INDUSTRY

NCT07156773 - The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes | Biotech Hunter | Biotech Hunter